New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 22, 2014
09:07 EDTSNTASynta Pharmaceuticals data positive, says JMP Securities
JMP Securities believes that early top-line data indicates Synta's ganetespib plus current standard of care, low-dose Ara-C provide clinical benefit in high-risk elderly patients with newly diagnosed AML and MDS. The firm says the results increase its confidence in a positive GALAXY-2 outcome in NSCLC and broad applicability of ganetespib across a variety of tumor types. It keeps an Outperform rating on the stock.
News For SNTA From The Last 14 Days
Check below for free stories on SNTA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for SNTA

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use